Stocks
Fulcrum Therapeutics, Inc.FULC
NASDAQHealthcareBiotechnology$3.68
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing small molecule therapies for rare genetic diseases, with a lead candidate targeting facioscapulohumeral muscular dystrophy (FSHD). Investors track the company for its progress in Phase 3 trials and potential first-to-market status in this niche indication.
52W Range: $2.83-$15.74
Congressional Interest in Fulcrum Therapeutics, Inc. (FULC)
No congressional trades have been disclosed for Fulcrum Therapeutics, Inc. (FULC) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading FULC?
No congressional trades found for this stock.